Diabetes drugs linked to increased CV risk
THE TGA is considering whether additional precautions are warranted for a number of the sulfonylureas within the class of insulin secretagogues, following a study suggesting they are associated with increased mortality and cardiovascular risk.
A TGA spokesperson said findings from the European Heart Journal study, comparing insulin secretagogue monotherapy with metformin, were being reviewed.
The Danish authors followed more than 100,000 subjects who had received insulin secretagogues or metformin for nine years.
They found increased all-cause